# NovaSure Endometrial Ablation Aggregate Data

After 14 years of treating AUB with minimally invasive, safe, non-hormonal treatment, the NovaSure endometrial ablation system has time tested and durable results. The proven high rate of success, amenorrhea and patient satisfaction are not only a testament to the 2 million women treated but also are confirmed through long-standing, extensive, prospective clinical data.

The below data is representative of:
- Over 700 subjects
- 10 peer-reviewed publications
- A proven record of safety and efficacy

### METHODOLOGY:
Ten prospective studies, six single-arm NovaSure trials and four randomized controlled trials were reviewed for amenorrhea rate, success rate and patient satisfaction. The follow-up period for these measures was 12 months. Studies were chosen based on similar protocols and endpoints.

### REFERENCES:

### NovaSureAggregate Data - Bibliography

### NOTE:
Please refer to the IFU for risk information.

---

<table>
<thead>
<tr>
<th>PBLAC ≤ 75 (n=403)</th>
<th>Reduction in bleeding (n=112)</th>
<th>Total (n=515)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combined Success rates*</td>
<td>87.1%</td>
<td>77.7%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PBLAC = 0 (n=605)</th>
<th>No bleeding (n=75)</th>
<th>Total (n=680)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combined Amenorrhea rates*</td>
<td>46.1%</td>
<td>52%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Combined Patient satisfaction**</th>
<th>93.7%</th>
</tr>
</thead>
</table>

*1-year rates based on an intent-to-treat population
**1-year rates based on an evaluable.